Compare BNGO & HCWB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BNGO | HCWB |
|---|---|---|
| Founded | 2003 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Laboratory Analytical Instruments | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 13.3M | 14.8M |
| IPO Year | 2018 | 2021 |
| Metric | BNGO | HCWB |
|---|---|---|
| Price | $1.14 | $1.08 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 1 |
| Target Price | $7.00 | ★ $35.00 |
| AVG Volume (30 Days) | 133.8K | ★ 1.3M |
| Earning Date | 05-13-2026 | 05-15-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 94.50 | N/A |
| EPS | N/A | ★ 0.37 |
| Revenue | ★ $12,000,735.00 | $4,099,750.00 |
| Revenue This Year | $14.99 | N/A |
| Revenue Next Year | $34.73 | N/A |
| P/E Ratio | ★ N/A | $2.92 |
| Revenue Growth | ★ 26.26 | N/A |
| 52 Week Low | $1.06 | $0.25 |
| 52 Week High | $5.50 | $7.35 |
| Indicator | BNGO | HCWB |
|---|---|---|
| Relative Strength Index (RSI) | 38.97 | 44.09 |
| Support Level | $1.09 | $1.03 |
| Resistance Level | $1.18 | $1.17 |
| Average True Range (ATR) | 0.04 | 0.16 |
| MACD | -0.01 | -0.08 |
| Stochastic Oscillator | 0.00 | 14.20 |
Bionano Genomics Inc is a life sciences instrumentation company in the genome analysis space. It is engaged in the development and marketing of the Saphyr system, a platform for ultra-sensitive and ultra-specific structural variation detection that enables researchers and clinicians to accelerate the search for new diagnostics and therapeutic targets and to streamline the study of changes in chromosomes. Geographically, it operates in the Americas, EMEA, and Asia Pacific, of which the EMEA region generates the majority of its revenue. It generates product revenue from sales of its OGM and Ionic Purification systems and consumables, which include its instruments and their VIA software.
HCW Biologics Inc is a clinical-stage biopharmaceutical company developing transformative fusion immunotherapeutics to support or treat diseases promoted by chronic inflammation. It has created novel compounds that represent a new class of drugs that it believes has the potential to fundamentally change the treatment of autoimmune disorders and other proinflammatory diseases, cancer and senescence-associated dysplasia. The company has developed two proprietary drug discovery and development platforms which it uses to create novel fusion immunotherapeutics: The TOBI (Tissue factOr-Based fusIon) platform, and The T-cell Receptor Beta Chain constant region (TRBC) platform. It operates and manages its business as one reportable segment.